loading page

AHU 377 is commercially hidden molecula?
  • Zaur Gasimov
Zaur Gasimov
Research Institute of Cardiology named after J.Abdullayev

Corresponding Author:[email protected]

Author Profile

Abstract

ARNI-drug, which consists of two components: the blocker of angiotensin receptors -valsartan and the neprilysin inhibitor-sacubitril. As a rule, the drugs available in cardiological practice, both two-component and fixed 3 or more component, consist of a combination of drugs that are successfully used as monotherapy. Examples include calcium antagonists, β-blockers, hydrochlorothiazide, indapamide, valsartan, perindopril, etc. All these drugs have been used successfully for many years as monotherapy, and nowadays, both as monotherapy and in combinations.But sacubitril is only drug in cardiovascular practice which is not recommended as monotherapy,only as combination – sacubitril/valsartan. LCZ 696 were represented by drug makers as very difficult to create, even at 696 attempt, < monolith molecule>. Cause of ? The reason is not entirely clear and, as I understand it, is explained by the necessity of compulsory fusion into a for the simultaneous release of both components of both valsartan and sacubitrile so that valsartan mitigates the negative effect of sacubitril caused NEP-dependent degradation of angiotensin II.Weak explanation,isn’t it? But No sacubitril monotherapy studies were conducted. However, a sacubitril 200 mg monotherapy arm of 165 patients was included in the HTN study CLCZ696A2201. A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension. In monotherapy arm, participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan.